Sicherheit, Verträglichkeit, Pharmakokinetik, Pharmakodynamik und Wirksamkeit von SAR442501 bei pädiatrischen Teilnehmern mit Achondroplasie (upreACH-2)
1. Juni 2026 aktualisiert von: Sanofi
Eine offene, multizentrische, zweistufige sequentielle Kohorten-Dosiseskalationsstudie der Phase 2 zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik, Pharmakodynamik und Wirksamkeit von subkutanem SAR442501 bei pädiatrischen Teilnehmern mit Achondroplasie
Dies ist eine offene, multizentrische Phase-2-Studie zur Bewertung der Sicherheit, Verträglichkeit und Wirksamkeit von SAR442501 bei Kindern von der Geburt bis zum Alter von 12 Jahren mit Achondroplasie.
Studienübersicht
Detaillierte Beschreibung
Bis zu etwa 275 Wochen: 3 Wochen Screening + 52 Wochen Erstbehandlungszeitraum + bis zu etwa 216 Wochen verlängerter Behandlungszeitraum + 4 Wochen Nachbeobachtung.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
16
Phase
- Phase 2
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Victoria
-
Parkville, Victoria, Australien, 3052
- Investigational Site Number : 0360001
-
-
-
-
-
Shanghai, China, 200120
- Investigational Site Number : 1560002
-
Wuhan, China, 430030
- Investigational Site Number : 1560001
-
-
-
-
Lombardy
-
Milan, Lombardy, Italien, 20122
- Investigational Site Number : 3800002
-
-
Roma
-
Rome, Roma, Italien, 00168
- Investigational Site Number : 3800001
-
-
-
-
Basque Country
-
Vitoria-Gasteiz, Basque Country, Spanien, 01008
- Investigational Site Number : 7240002
-
-
Catalunya [Cataluña]
-
Esplugues de Llobregat, Catalunya [Cataluña], Spanien, 08950
- Investigational Site Number : 7240001
-
-
-
-
Seoul-teukbyeolsi
-
Seoul, Seoul-teukbyeolsi, Südkorea, 03080
- Investigational Site Number : 4100001
-
Seoul, Seoul-teukbyeolsi, Südkorea, 06351
- Investigational Site Number : 4100002
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Kind
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Einschlusskriterien:
- Teilnehmer müssen ACH mit einer bestätigten Mutation im FGFR3-Gen haben
- Teilnehmer und/oder Eltern oder gesetzliche Vertreter müssen bereit und in der Lage sein, alle Studienabläufe im Rahmen ihrer körperlichen Leistungsfähigkeit durchzuführen.
- Eltern oder gesetzliche Vertreter, die in der Lage sind, eine unterzeichnete Einverständniserklärung abzugeben, und Teilnehmer, die in der Lage sind, gegebenenfalls ihre Zustimmung zu erteilen.
Ausschlusskriterien:
- Hypochondroplasie (oder die N540K-Mutation) oder eine andere Kleinwuchserkrankung als ACH haben (z. B. Trisomie 21, Pseudochondroplasie)
- Die Teilnehmer haben innerhalb von 6 Monaten nach der Einschreibung (Woche 0/Tag 1/Besuch 2) eine beliebige Dosis an Medikamenten oder Prüfpräparaten, einschließlich menschlichem Wachstumshormon, erhalten, die die Statur oder Körperproportionen der Teilnehmer beeinflussen sollen.
- In der Vergangenheit kam es zum Verschluss der Wachstumsfuge.
- Bruch der Röhrenknochen innerhalb von 3 Monaten nach der Einschreibung (Woche 0/Tag 1/Besuch 2)
- Aktuelle Hinweise auf eine Hornhaut- oder Netzhauterkrankung/Keratopathie.
- Die Teilnehmer hatten zuvor einen chirurgischen Eingriff am Foramen magnum (nur Stadium 2).
- Hyperphosphatämie.
Die oben genannten Informationen sollen nicht alle Überlegungen enthalten, die für eine mögliche Teilnahme an einer klinischen Studie relevant sind.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Kohorte 1
|
Injektionslösung; Subkutane Injektion
|
|
Experimental: Kohorte 2
|
Injektionslösung; Subkutane Injektion
|
|
Experimental: Kohorte 3
|
Injektionslösung; Subkutane Injektion
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Stage 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Zeitfenster: From the first dose of study drug administration (Day 1) up to early termination of the study, approximately 58 weeks (Stage 1: SAR442501 Dose A) and 46 weeks (Stage 1: SAR442501 Dose B)
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug.
An SAE was defined as any untoward medical occurrence (whether considered to be related to study drug or not) that at any dose: resulted in death; or was life-threatening; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect; or was an important medical event.
An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.
The TEAEs were defined as events that were newly reported or reported to worsen in severity after the start of study drug up to 5 days post last dose of the study drug.
|
From the first dose of study drug administration (Day 1) up to early termination of the study, approximately 58 weeks (Stage 1: SAR442501 Dose A) and 46 weeks (Stage 1: SAR442501 Dose B)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Growth Velocity Z-Score
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
Post-treatment annualized growth velocity (AGV) was calculated from height measurements collected during the study.
AGV was calculated as: AGV (centimeter per year)= (Height at Date 2 - Height at Date 1) divided by interval length in days x 365.25,
where interval length in days was calculated as (Date 2 - Date 1+1).
Z scores were calculated using LMS methods (Box Cox power L, Median M and Variation S), where appropriate: If L≠ 0: Z= [(AGV/M)^L-1]/(LxS); If L= 0: Z= ln(AGV/M)/S.
A Z score of 0 represents the mean AGV of the reference achondroplasia (ACH) population.
For AGV Z scores in children with ACH: Higher Z scores represent better outcomes, meaning faster linear growth relative to age and sex matched reference populations.
Lower Z scores represent worse outcomes, indicating slower growth compared to reference norms.
Baseline value was defined as last available pre dose height measurement meeting statistical analysis plan specified time interval definitions.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Annualized Growth Velocity
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The AGV was defined as follows: (Height at Date 2 - height at Date 1) divided by interval length in days x 365.25,
where the interval length in days was calculated as (Date 2 - Date 1 +1) days.
The post-treatment AGV was calculated from height measurements collected during the study.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Height Z-Score
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
Post-treatment AGV was calculated from height measurements collected during the study.
AGV was calculated as: AGV (centimeter per year)= (Height at Date 2 - Height at Date 1) divided by interval length in days x 365.25,
where interval length in days was calculated as (Date 2 - Date 1+1).
Z scores were calculated using LMS methods (Box Cox power L, Median M and Variation S), where appropriate: If L≠ 0: Z= [(AGV/M)^L-1]/(LxS); If L= 0: Z= ln(AGV/M)/S.
A Z score of 0 represents the mean AGV of the reference population (ACH).
For AGV Z scores in children with ACH: Higher Z scores represent better outcomes, meaning faster linear growth relative to age and sex matched reference populations.
Lower Z scores represent worse outcomes, indicating slower growth compared to reference norms.
Baseline value was defined as last available pre dose height measurement meeting statistical analysis plan specified time interval definitions.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Upper to Lower Body Segment Ratio
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The upper to lower body segment ratio was calculated by (standing height or total length - lower body segment length) divided by lower body segment length.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Upper to Lower Extremity Ratio
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The upper to lower extremity ratio was calculated by (upper arm + forearm length) divided by (upper leg + lower leg length).
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Sitting to Standing Height Ratio
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The sitting to standing height ratio was calculated by sitting height divided by standing height, or crown to rump length divided by total length.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Arm Span to Height Ratio
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The arm span to height ratio was calculated by arm span divided by standing height, or arm span divided by total length.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Upper Arm to Forearm Length Ratio
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The upper arm to forearm length ratio was calculated by upper arm length divided by forearm length.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Upper Leg to Lower Leg Ratio
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The upper leg to lower leg length ratio was calculated by upper leg length divided by lower leg length.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Head Circumference to Height Ratio
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The head circumference to height ratio was calculated by head circumference divided by standing height, or head circumference divided by total length.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 2: Change From Baseline to Week 52 in Brainstem, Skull, and Spine Morphometric and Volumetric Parameters
Zeitfenster: Baseline (Day 1) and Week 52
|
The magnetic resonance imaging was planned to be collected to measure foramen magnum and other brainstem, skull, and spine morphometric parameters in Stage 2 participants.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Week 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Social Score, Emotional Score, and School Functioning Score
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The pediatric quality of life (PedsQL) Generic Core Scales assesses pediatric health related quality of life (HRQOL) across functioning domains.
Items use a 5-point scale (0=Never to 4=Almost Always).
Responses are reverse scored and linearly transformed to a 0-100 scale (0→100, 1→75, 2→50, 3→25, 4→0), where higher scores indicate better quality of life (fewer problems).
Domain scores for Social, Emotional, and School Functioning are calculated from the transformed item scores.
If more than 50% of items in a domain are missing, the domain score is not computed.
If at least 50% are completed, the domain score equals the mean of the non missing transformed item scores.
All domain scores range from 0 (almost always) to 100 (never), with higher scores indicate better HRQOL.
Baseline was defined as the last available value prior to the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Psychosocial Health Summary Score, Physical Health Summary Score, and Total Score
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The PedsQL core scale was a brief, standardized, generic instrument that was used to measure HRQOL in various pediatric conditions.
Psychosocial health summary scores were the meaning of item scores in emotional, social, and school functioning scales; and Physical health summary scores were the meaning of item scores in physical scale.
Total score was the mean of all the item scores in all scales.
Psychosocial and physical health summary scores and total scores each ranged from 0 (almost always) to 100 (never).
Higher scores indicate better HRQOL.
For participants aged 5 to 7, only parents completed the questionnaire.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Mobility Score
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The screening tool for everyday mobility and symptoms (STEMS) was completed by clinicians for participants 5 years of age and older.
The STEMS captures mobility, use of mobility aides, and impact of pain and/or fatigue at the end of the day across 3 environments: home, school/work and community.
Mobility aides were recorded using numeric 5-point rating scale, score ranged from 1 to 5, where 1= independent on all surfaces including stairs, 2= use of sticks, 3= use of crutches, 4= use of wheeled walking device, and 5= use of wheelchair or mobility scooter.
Lower score indicated the better outcome.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Participants Reported Symptoms
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The STEMS was completed by clinicians for participants 5 years of age and older.
The STEMS captures mobility, use of mobility aides, and impact of pain and/or fatigue at the end of the day across 3 environments: home, school/work and community.
Participant reported symptoms were recorded using letters where A= no pain or fatigue, B1= pain only, B2= fatigue and C= pain and fatigue.
This was completed for each of the 3 environments resulting in 3 scores, whereby the numeric rating reflects the use of mobility aides and the letter reflects the symptoms.
The baseline value was defined as the last available value before the first dose of study drug.
Only participants with a Baseline response of "A" were included in the "A to A," "A to B1," and "A to missing" categories at each time point.
Similarly, only participants with a Baseline response of "B1" were included in the "B1 to A" and "B1 to missing" categories at each time point.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in General Fatigue, Sleep/Rest Fatigue and Cognitive Fatigue Scores and Total Score
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The PedsQL Multidimensional Fatigue Scale measures fatigue across 3 subscales:General Fatigue, Sleep/Rest Fatigue and Cognitive Fatigue.
Items are rated on a 5 point scale (0=Never to 4=Almost Always).
Responses are reverse scored and linearly transformed to a 0-100 scale (0→100, 1→75, 2→50, 3→25, 4→0), with higher scores indicate less fatigue and better functioning.
Subscale scores are calculated as mean of transformed item scores within each subscale.
A Total Score was calculated as mean of all transformed items across subscales.
If more than 50% of items are missing within a subscale or across total scale, corresponding score is not computed.
If at least 50% are completed, scores are calculated as mean of non missing transformed items.
All scores range from 0 (no pain) to 100 (severe pain), with higher scores indicate less fatigue.
Baseline was defined as last available value prior to first dose of study drug.
For participants aged 5-7 years, only parent proxy report was completed.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Current Pain and Worst Pain Rating (PPQ) Score
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
The PedsQL PPQ assesses current pain and worst pain intensity in the last week using a visual analog scale as well as pain location using a body map.
Current and worst pain were scored separately, and scoring was based on the line length to the nearest 0.5 centimeter (5 millimeter).
The score ranged from 0 (no pain) to 100 (severe pain), where higher scores indicated greater levels of pain intensity.
The PedsQL PPQ was only administered in participants ages 5 years of age and older using both self-report (ages 8 and older) and parent proxy report (ages 5 and older) forms in all countries.
For participants aged 5 to 7, only parents completed the questionnaire.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 2: Change From Baseline to Week 52 in Achievement of Gross Motor, Fine Motor, Communication, and Feeding Milestones
Zeitfenster: Baseline (Day 1) and Week 52
|
For Stage 2 participants, achievement of developmental milestones was planned to be assessed using the ACH developmental recording form.
This form allows developmental milestones to be recorded and was not a formalized screening tool or assessment.
The form measures the domains of gross motor function, fine motor function, communication and feeding via participant reports to the Investigator.
The form depicts the cumulative percentage distributions for children with ACH for each item as well as norms for reference based on the Denver II test, where available.
Data collected via this form was planned to be evaluated descriptively to explore the age at which participants in this study achieve developmental milestones.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Week 52
|
|
Stage 1: Plasma Concentration of SAR442501
Zeitfenster: Pre-dose and 6, 24 and 72 hours post dose on Day 1; Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
|
Blood samples are collected to determine plasma concentration of SAR442501.
|
Pre-dose and 6, 24 and 72 hours post dose on Day 1; Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
|
|
Stage 1: Maximum Observed Plasma Concentration (Cmax) of SAR442501
Zeitfenster: Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
|
Blood samples are collected to determine Cmax of SAR442501.
The Cmax of SAR442501 was calculated using non-compartmental method.
|
Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
|
|
Stage 1: Time to Reach the Maximum Concentration (Tmax) of SAR442501
Zeitfenster: Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
|
Blood samples are collected to determine tmax of SAR442501.
The tmax of SAR442501 was calculated using non-compartmental method.
|
Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
|
|
Stage 1: Area Under the Concentration Versus Time Curve From Time 0 to 72 Hours After Study Drug Administration (AUC0-tau) of SAR442501
Zeitfenster: Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
|
Blood samples are collected to determine AUC0-tau of SAR442501.
The AUC0-tau of SAR442501 was calculated using non-compartmental method.
|
Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
|
|
Stage 1: Minimum Plasma Concentration (Ctrough) of SAR442501
Zeitfenster: Pre-dose on Days 8, 29, 57, 92, 183, 274, 365 and 449
|
Blood samples are collected to determine Ctrough of SAR442501.
The Ctrough of SAR442501 was calculated using non-compartmental method.
|
Pre-dose on Days 8, 29, 57, 92, 183, 274, 365 and 449
|
|
Stage 1: Change From Baseline to Week 26 in Collagen X Biomarker (CXM) Level
Zeitfenster: Baseline (Day 1) and Week 26
|
Serum samples were collected to assess the change in CXM level with study drug.
The CXM was also named PRO-C10 because the biomarker assay used was aimed to target the recognition of the C terminus of the NC1 domain of type X collagen.
The baseline value was defined as the last available value before the first dose of study drug.
Change from baseline in CXM level has been reported.
|
Baseline (Day 1) and Week 26
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Osteocalcin Level
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
Serum samples were collected to assess the change in osteocalcin level with study drug.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Bone-Specific Alkaline Phosphatase Level
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
Serum samples were collected to assess the change in bone-specific alkaline phosphatase level with study drug.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Procollagen Type 1 N-Terminal Propeptide (P1NP) Level
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
Serum samples were collected to assess the change in P1NP level with study drug.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Change From Baseline to Weeks 26 and 52 in Collagen-Type 1 C-Telopeptide (CTX) Level
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
Serum samples were collected to assess the change in CTX level with study drug.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
|
Stage 1: Number of Participants With Anti-drug Antibodies (ADA) to SAR442501
Zeitfenster: From the first dose of study drug administration (Day 1) up to early termination of the study, approximately 58 weeks (Stage 1: SAR442501 Dose A) and 46 weeks (Stage 1: SAR442501 Dose B)
|
Serum samples were collected to assess the antibodies to SAR442501.
Samples were screened and then confirmed for antibodies binding to SAR442501 and the titer of confirmed positive samples were reported.
Positive ADA refers to pre-existing ADA at the pre-dose assessment on Day 1.
|
From the first dose of study drug administration (Day 1) up to early termination of the study, approximately 58 weeks (Stage 1: SAR442501 Dose A) and 46 weeks (Stage 1: SAR442501 Dose B)
|
|
Stage 2: Number of Participants With Change From Baseline to Weeks 26 and 52 in Neurological Examination Findings
Zeitfenster: Baseline (Day 1) and Weeks 26 and 52
|
A complete neurological examination included assessment of mental status, motor function and balance, sensory exam, newborn and infant reflexes, muscle stretch reflexes in the older children and evaluation of the cranial nerves.
The baseline value was defined as the last available value before the first dose of study drug.
|
Baseline (Day 1) and Weeks 26 and 52
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Studienleiter: Clinical Sciences & Operations, Sanofi
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Nützliche Links
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
10. Oktober 2023
Primärer Abschluss (Tatsächlich)
12. Februar 2025
Studienabschluss (Tatsächlich)
12. Februar 2025
Studienanmeldedaten
Zuerst eingereicht
20. September 2023
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
28. September 2023
Zuerst gepostet (Tatsächlich)
4. Oktober 2023
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
25. Juni 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
1. Juni 2026
Zuletzt verifiziert
1. Mai 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- DRI16646
- U1111-1280-5374 (Registrierungskennung: ICTRP)
- 2023-503677-37 (Registrierungskennung: CTIS)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
JA
Beschreibung des IPD-Plans
Qualifizierte Forscher können Zugriff auf Daten auf Patientenebene und zugehörige Studiendokumente anfordern, einschließlich des klinischen Studienberichts, des Studienprotokolls mit etwaigen Änderungen, eines leeren Fallberichtsformulars, eines statistischen Analyseplans und der Datensatzspezifikationen.
Daten auf Patientenebene werden anonymisiert und Studiendokumente werden geschwärzt, um die Privatsphäre der Studienteilnehmer zu schützen.
Weitere Einzelheiten zu den Datenfreigabekriterien von Sanofi, förderfähigen Studien und dem Verfahren zur Beantragung des Zugriffs finden Sie unter: https://vivli.org
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Ja
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .